negligible immunogenicity terminally differentiated cells derived induced pluripotent embryonic stem cells 
advantages using induced pluripotent stem cells ipscs instead embryonic stem es cells regenerative medicine centre around circumventing concerns ethics using es cells likelihood immune rejection es-cell-derived tissues however partial reprogramming genetic instabilities ipscs- elicit immune responses transplant recipients even ipsc-derived differentiated cells transplanted ipscs first differentiated specific types cells vitro subsequent transplantation although model transplantation experiments conducted using various ipsc-derived differentiated tissues- immune rejections observed careful investigation immunogenicity ipsc-derived tissue becoming increasingly critical especially focus studies done far recent study reported immunogenicity ipsc es-cell-derived teratomas implicated several causative genes nevertheless controversy arisen regarding findings examine immunogenicity differentiated skin bone marrow tissues derived mouse ipscs ensure optimal comparison ipscs es cells established ten integration-free ipsc seven es-cell lines using inbred mouse strain c57bl/ observed differences rate success transplantation skin bone marrow cells derived ipscs compared es-cell-derived tissues moreover observed limited immune responses including t-cell infiltration tissues derived either ipscs es cells increase expression immunogenicity-causing zg16 hormad1 genes regressing skin teratoma tissues findings suggest limited immunogenicity transplanted cells differentiated ipscs es cells 
